Okay, let's start by figuring out the core concept here. The question is about a drug that inhibits post-translational modification of viral proteins. Post-translational modifications (PTMs) are crucial for the function of many viral proteins. Common PTMs include glycosylation, phosphorylation, and proteolytic cleavage. So the drug in question likely targets an enzyme involved in one of these processes.

Now, the correct answer is probably related to a specific virus. Let's think about common antiviral drugs. For example, HIV protease inhibitors prevent the cleavage of viral polyproteins, which is a form of post-translational modification. Similarly, some antiviral drugs inhibit glycosylation, which is important for the structure of envelope proteins in viruses like HIV or influenza.

Looking at the options, if one of them is a protease inhibitor, that would make sense. For instance, ritonavir or lopinavir are HIV protease inhibitors that prevent the processing of viral proteins. If the question is about a different virus, maybe a different enzyme is targeted. But HIV protease inhibitors are a classic example here.

The incorrect options might include drugs that work through other mechanisms. For example, nucleoside analogs like acyclovir inhibit viral DNA synthesis, reverse transcriptase inhibitors prevent RNA to DNA conversion, and entry inhibitors block viral entry into the host cell. These don't target post-translational modifications.

Clinical pearl: Remember that protease inhibitors are used in HIV and HCV treatment and work by inhibiting the cleavage of viral polyproteins, which is essential for producing functional viral particles. This is a key high-yield point for exams.

**Core Concept**
Post-translational modification (PTM) of viral proteins, such as proteolytic cleavage or glycosylation, is critical for viral replication. Drugs targeting enzymes responsible for these modifications (e.g., proteases) can block viral maturation.

**Why the Correct Answer is Right**
Protease inhibitors, like **ritonavir** or **lopinavir**, specifically inhibit the viral protease enzyme. This prevents cleavage of viral polyproteins into functional units (e.g., gag-pol proteins in HIV), halting maturation of infectious virions. By blocking this PTM step, the virus cannot assemble properly.

**Why Each Wrong Option is Incorrect**
**Option A:** Nucleoside analogs (e.g., acyclovir) inhibit viral DNA polymerase, not PTM.
**Option B:** Reverse transcriptase inhibitors (e.g., zidovudine) block RNA→DNA conversion in retroviruses, unrelated to PTM.
**Option C:** Entry inhibitors (e.g., enfuvirtide) prevent viral fusion with host cells, bypassing PTM.

**Clinical Pearl / High-Yield Fact**
Protease inhibitors are cornerstone drugs in HIV and HCV therapy. Remember: they target **cleavage of polyproteins**—a classic PTM step. Confusion with nucleoside analogs or entry inhibitors is common in exams.

**Correct Answer: D. Protease inhibitors**

✓ Correct Answer: A. Indinavir